Immunotherapy Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Immunotherapy Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Endometrial Cancer Therapy
Investigators at Jikei University target endometrial cancer therapy
April 11th, 2007
Fresh data on endometrial cancer are presented in the report "Association of extracellular matrix metalloproteinase inducer in endometrial carcinoma with patient outcomes and clinicopathogenesis using monoclonal antibody 12C3. Extracellular matrix metalloproteinase inducer (EMMPRIN) is a member of the immunoglobulin superfamily of adhesion molecules and has a role in the activation of several matrix metalloproteinases (MMPs). We evaluated whether EMMPRIN expression is related to tumor progression and patient outcome in human endometrial carcinoma," investigators in Tokyo, Japan report. "Paraffin-embedded surgical tissue samples from 112 patients with endometrial...
Source: Immunotherapy Weekly (2007-04-11)
|
